Well maybe you should read the whole article before you get too excited?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775099/
Cardiac MRI revealed no significant difference between the groups in changes in LVEDV (P = .87) or LVESV (P = .79) from baseline to 12 months. The median LVEDV at 12 months was 40.4 mL/m2 (IQR, 29.2-73.9 mL/m2) in the MPC group and 47.6 mL/m2 (IQR, 37.7-52.4 mL/m2) in the control group. As demonstrated in the 3D echocardiography data, there was no significant difference between the groups in changes in LV mass (P = .71) or LV ejection fraction (P > .99). These imaging data are presented in Table 3 and Figure 5. The 2D echocardiography data showed similar trends as the 3D measurements (Table E1).
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-226
-
- There are more pages in this discussion • 155 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |